Post-transplant hepatocellular carcinoma: balancing immunosuppression and immune checkpoint inhibitors
Year: 2026
Type: review
Abstract: Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and hepatocellular carcinoma (HCC). Advances in surgical techniques and immunosuppressive regimens have markedly improved early post-transplant survival. However, long-term outcomes remain compromised by HCC recurrence, chronic rejection, metabolic complications, and de novo malignancies. Recurrence of HCC after LT remains a major clinical challenge, with available prognostic models providing limited accuracy in risk stratification. Simultaneously, systemic therapies for unresectable HCC have rapidly advanced, particularly with immune checkpoint inhibitors (ICIs), providing new opportunities and unique challenges in transplant settings. With ICIs carrying a risk of acute and potentially fatal rejection and lacking controlled data on efficacy or safety in the post-transplant setting, tyrosine kinase inhibitors currently represent a standard option for post-transplant recurrence. Novel biomarkers, such as donor-derived cell-free DNA and the gut microbiome, are emerging as potential tools to refine risk stratification and guide immunosuppression. Furthermore, innovative immunotherapies, including oncolytic viruses and mRNA vaccines, are being explored as tumor-specific approaches. Collectively, these advances may reshape future management of LT recipients.
Institution: The University of Tokyo
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: hepatocellular carcinoma, liver transplantation, HCC recurrence, immune checkpoint inhibitors, immunosuppression, acute rejection, tyrosine kinase inhibitors, donor-derived cell-free DNA, gut microbiota, risk stratification, oncolytic viruses, mRNA vaccines, de novo malignancy, chronic rejection
Open Access status: gold
Estimated APC paid: $32
OpenAlex ID: W7127048744
